Warner Chilcott
 | |
| Subsidiary | |
| Industry | Pharmaceutical |
| Founded | 1968 |
| Founder | Allen McClay |
| Headquarters | Rockaway, New Jersey, United States |
| Products | Drugs |
| Parent | Actavis |
| Website |
www |
Warner Chilcott (formerly Galen) is a pharmaceutical company based in Rockaway, New Jersey, United States. It has production and research facilities in Fajardo, Puerto Rico, Larne, Northern Ireland, Dundalk, Republic of Ireland and Weiterstadt, Germany. It is primarily focused on two core therapeutic areas: women’s healthcare and dermatology. The company has 2700 employees worldwide, 1700 of which are based in the United States.[1] The company established its corporate headquarters in Dublin, Republic of Ireland in 2010.[2]
History
In 1968, the Company was founded by Sir Allen McClay as Galen, a sales and marketing organisation focused on branded pharmaceutical products in the UK and Republic of Ireland. The company listed its shares on the London Stock Exchange and Irish Stock Exchange.
In 2000, Galen acquired the Warner Chilcott, a US pharmaceutical company, which is focused on women’s healthcare, and simultaneously listed its ADRs on NASDAQ. In 2004, the company changed its name from Galen to Warner Chilcott.
On October 30, 2009, Warner Chilcott closed a deal to acquire Procter & Gamble's prescription-drug business for $3.1 billion, according to the Wall Street Journal; the deal had been announced on August 24, 2009.
Warner Chilcott markets Sarafem (fluoxetine or 'Prozac') which is manufactured by Eli Lilly and Company.[3]
On May 20, 2013, Actavis and Warner Chilcott announced that they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott in a stock-for-stock transaction valued at approximately $8.5 billion.[4]